Press Releases May 4, 2026 05:00 AM

Ambarella Announces First Quarter Fiscal Year 2027 Earnings Conference Call to be Held May 28, 2026

Ambarella schedules Q1 FY2027 earnings call for May 28, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
AMBA

Ambarella, Inc., an edge AI semiconductor company, announced that it will hold its first quarter fiscal year 2027 earnings conference call on May 28, 2026. The company plans to release its earnings after market close the same day, with a webcast and live call available to registered participants.

Ambarella Announces First Quarter Fiscal Year 2027 Earnings Conference Call to be Held May 28, 2026
AMBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ambarella focuses on edge AI semiconductor solutions with an installed base of over 42 million AI SoC units.
  • Its products are used in diverse sectors including physical security, vehicle safety, telematics, aerial drones, and robotics.
  • Company offers a full-stack edge AI platform featuring optimized silicon, software, and AI frameworks enabling machine autonomy.

SANTA CLARA, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its first quarter fiscal year 2027 earnings conference call on Thursday, May 28, 2026, at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day.

Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the dial-in numbers will be sent to the registered email with a personal identification number (PIN). When dialing in for the live call, the PIN number must be provided to access the call.

The live webcast of the conference call, and a webcast replay, will be available at: http://investor.ambarella.com/events.cfm

About Ambarella

With an installed base of more than 42 million AI SoC units, Ambarella’s products are utilized in a wide variety of physical edge AI applications, spanning edge endpoint and edge infrastructure use cases including physical security, vehicle safety, telematics, autonomy, portable video, aerial drones, and other emerging robotic applications. Building on this footprint, Ambarella offers a full-stack edge AI platform, from highly optimized silicon and programmable software to AI agentic frameworks that coordinate perception, decision-making and control across devices. Ambarella’s low-power systems-on-chip (SoCs) integrate proprietary and highly efficient perception and deep learning neural network AI accelerators, enabling electronic systems to become more productive with partial or complete levels of machine autonomy.  For more information, please visit www.ambarella.com.

Contact:
Louis Gerhardy
VP Corporate Development
408-636-2310
lgerhardy@ambarella.com


Risks

  • Financial performance may not meet investor expectations revealed during the earnings call.
  • Market competition in the semiconductor and AI edge processing sectors could affect Ambarella's growth.
  • Dependence on emerging technology adoption in sectors such as automotive and robotics introduces uncertainty.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026